AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03799952 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Zoomers on the Go Exercise Program
Description: 60 minute exercise class involving resistance and aerobic training activities, as well as flexibility and balance activities. An educational handout is offered at the end of every class, relating to health behaviour.
Study NCT00335738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal vincristine sulfate
Description: Given IV
Study NCT00335738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT00335738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT02217514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 44370 medium dose
Study NCT02217514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 44370 high dose
Study NCT03636880 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Monitoring
Description: This intervention involves using sleep diaries to track daily aspects of sleep, including bed time, wake time, hours of sleep, nighttime awakenings, daytime naps, and sleep quality.
Study NCT01082341 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunization with P. vivax irradiated sporozoites
Description: Anopheles albimanus mosquitoes will be infected by artificial membrane feeding using blood from P. vivax infected donors. Once mosquitoes are positive will be irradiated at 15000 cGy and kept in boxes until use.~14 Fy(+) human volunteers in the experimental group will be immunized with 1,000-2,000 P. vivax irrad-spz bites. Seven Fy(+) volunteers in the control group will be exposed to non-infected mosquito bites. Six Fy(-) volunteers will be exposed to infective mosquito bites. For the challenge both the immunized and control groups will be exposed to 3 ± 1 infective mosquito bites. Volunteers will be closely monitored post infection and will be treated with antimalarials.
Study NCT01082341 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Immunization with P. vivax irradiated sporozoites
Description: Anopheles albimanus mosquitoes will be infected by artificial membrane feeding using blood from P. vivax infected donors. Once mosquitoes are positive will be irradiated at 15000 cGy and kept in boxes until use.~14 Fy(+) human volunteers in the experimental group will be immunized with 1,000-2,000 P. vivax irrad-spz bites. Seven Fy(+) volunteers in the control group will be exposed to non-infected mosquito bites. Six Fy(-) volunteers will be exposed to infective mosquito bites. For the challenge both the immunized and control groups will be exposed to 3 ± 1 infective mosquito bites. Volunteers will be closely monitored post infection and will be treated with antimalarials.
Study NCT02815358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Segmental Stabilization Exercises
Description: The stabilization program focuses on the reestablishment of motor control and coordination between deep and superficial trunk muscles. The exercise program is based on the following criteria progression: 1) Precise contraction of the transverse abdominal and multifidus muscles, keeping the lumbar spine in a neutral position (as the middle way between maximum flexion and extension, repeated three times); 2) Keep the neutral position for 10 repetitions of 10 seconds; 3) Perform exercises with lower limbs in different postures.
Study NCT02815358 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Exercises
Description: Home exercises include passive stretching and active mobilization of the spine.
Study NCT00378612 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cypher sirolimus eluting coronary stent
Description: Cypher® sirolimus eluting coronary stent ranging in diameters 2.5 to 3.5 mm and available in length from 8 to 33 mm.
Study NCT02413216 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TicHelper
Description: TicHelper.com is an 8-week online program designed to teach tic management skills. Content and activities included in TicHelper.com are based on existing empirically-supported treatments including Habit Reversal Training (HRT) and Comprehensive Behavioral Intervention for Tics (CBIT). TicHelper.com is designed to teach tic management skills including psychoeducation, relaxation training, awareness training, competing response training, and social support. It is also designed to teach patients/parents to recognize and reduce tic-exacerbating reactions and activities.
Study NCT02413216 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Internet Based Resources
Description: The Internet-Based Resources (IBR) condition is designed to provide patients/parents with access to a wide range of educational materials. These materials contain up-to-date information regarding what is known about tic disorders and their management. Materials covering medical, educational, and behavioral/psychological topics are provided.
Study NCT01445210 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous saphenous nerve block
Description: 0,2% Ropivacaine by elastomeric infusion pump at 5 ml/h for 48 postoperative hours
Study NCT01445210 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Isoton saline by elastomeric infusion pump at 5 ml/h for 48 postoperative hours
Study NCT01203020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfex 130 mg/m2 intravenous piggy back (IVPB) for 4 days (Day -6 to -3) pharmacokinetic (PK) samples for Busulfex dose adjustment drawn on Day -6
Study NCT01203020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 40 mg/m2 IVPB for 4 days (Day -6 to -3)
Study NCT02393248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Study NCT04227067 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: An electrical impulse is delivered to the skin around the painful area using pads attached to an electric generator.
Study NCT04227067 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM TENS
Description: A TENS generator without batteries is used. The pads are attached to the generator and to the skin around the painful area.
Study NCT02239367 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Depression Decision Aid
Description: The Depression Decision Aid protocol, integrated into the Electronic Health Record (EHR), is a streamlined adaptation of an in-person Shared Decision-Making intervention.
Study NCT01128881 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Factor IX Concentrate (purified, virus-inactivated)
Description: Intravenous injection/infusion; dose for prophylaxis: 20-40 IU/kg bodyweight, twice weekly (which may be adjusted to the subject´s bleeding pattern and lifestyle); dose for bleeding episodes and surgery: according to the Summary of Product Characteristics and the Product Information Leaflet of the respective country.
Study NCT02677623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridium
Study NCT02677623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Fluorescein
Study NCT02677623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Study NCT02677623 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal Saline
Study NCT00745290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl
Description: 200 mg bupivacaine HCl
Study NCT00745290 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: SKY0402
Description: 600 mg SKY0402 (study drug).
Study NCT03556670 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Total Worker Health
Description: The intervention combines organizational and individual level strategies. Participants will be given access to pedal stands, health and safety messaging, and other environmental modifications. Intervention activities that participants could be asked to complete include: computer based training, goal setting and behavioral self-monitoring, scripted team-based health and safety discussions, and team competitions with pedal stands. Supervisor participants could additionally be asked to complete additional computer based training, goal setting and behavioral self-monitoring of supportive behaviors, and inter-supervisor observations. The intervention is six-months in duration.
Study NCT00395304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate
Description: Dry-powder inhaler fluticasone 250 mcg bid (Flovent Diskus®, GlaxoSmithKline)
Study NCT00395304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate + salmeterol
Description: Dry-powder inhaler fluticasone + salmeterol combination 100 mcg/50 mcg bid (Advair Diskus®, GlaxoSmithKline)
Study NCT01449955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rapamycin
Description: Sirolimus is an FDA approved immunosuppressant drug used to prevent rejection in organ transplantation, and is especially useful in kidney transplants. It is non-toxic to kidneys, unlike other immunosuppressants. In this study, the medication will be administered once to see if it interferes with emotional memory reconsolidation. This is based on the fact that it inhibits the mammalian target of Rapamycin (mTOR) through directly binding the mTOR Complex1 (mTORC1). mTOR is a serine/threonine protein kinase that regulates cell growth, cell proliferation, cell motility, cell survival, protein synthesis and transcription.~a single dosage of 15mg will be administered during this study.
Study NCT01723488 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [F18] T808
Description: Dose for normal volunteer undergoing dosimetry evaluation will not exceed 20 mCi, dose for high probability of Alzheimer's and low probability Alzheimer's undergoing brain imaging only will not exceed 10 mCi
Study NCT01449955 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive
Study NCT04348435 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HB-adMSCs
Description: Hope Biosciences allogeneic adipose-derived mesenchymal stem cells
Study NCT00386048 — intervention group
Intervention type: BEHAVIORAL
Intervention: Brief Cognitive-Behavioral Pain Management Training
Description: Participants complete a manualized, single session of training which includes: (A) education about the causes of sickle cell pain, (B) education about how the nervous system processes pain signals, and (C) explanations of how one can use cognitive and behavioral treatment (CBT) strategies to decrease the extent of pain experienced (all based on how the nervous system processes pain). Four specific CBT skills are taught and practiced by the participant (Progressive muscle relaxation, Controlled Deep Breathing, Imagery, and Distraction). The protocol explicitly emphasizes the use of CBT as a complimentary pain management tool to use in addition to the standard of care methods.
Study NCT01519271 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exelon Patch (rivastigmine transdermal system)
Description: The Exelon Patch (rivastigmine transdermal system) is a Cholinesterase Inhibitor approved by the FDA to treat Alzheimer's and Parkinson's Disease Dementia.~5-10cm2 (4.6-9.5 mg of rivastigmine/24 hours )
Study NCT01519271 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patches
Description: The placebo patches will appear identical to the medication patches however they will be inactive (they will not contain rivastigmine).
Study NCT01664546 — intervention group
Intervention type: PROCEDURE
Intervention: Trophectoderm biopsy
Study NCT03556670 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Usual practice control
Study NCT01555996 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early and Intensive Occupational Therapy
Description: Intervention group:Standard non-pharmacological prevention plus early and intensive OT. Begin in the first 24 hours in CCU admission. OT areas:1)Multi-sensory stimulation:Intense external stimulation, increase alertness,2)Positioning: Fixtures like dorxi-flexion splints, devices for preventing edema,etc,3)Cognitive Stimulation: Awareness, orientation, attention, memory, calculation, praxis and language,4)Training Activities of Daily Living (ADL): Keep a daily routine and independence in hygiene, grooming and feeding,5)Upper Limb Motor Stimulation (ULMS): Activate functional movement and strength ,6)Family involvement.~General Guidelines for intervention: Visit of an OT twice a day, 40 minutes each time, for 5 days; meeting of family training for promote strategies during the daily visit.
Study NCT01555996 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard non-pharmacological delirium prevention
Description: Non-pharmacological strategies are the first line of approach in the prevention of delirium. It is recommended to implement some of these strategies, which are: Reorientation protocol, including information 4 times a day about time, date, place and reason for hospitalization; early mobilization by physical therapist 3 times a day, corrected sensory impairment (use such as eyeglasses, hearing aids); environment management, use clock and calendar in the patient´s room, promote supervision of a professional or family to avoid physical restraints; sleep protocol, like lower light, noise and nighttime drug administration and finally, reduction of any anticholinergic drugs and minimize the use of benzodiazepines.
Study NCT01326143 — intervention group
Intervention type: DEVICE
Intervention: ORM Narval MRD
Study NCT01948297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio1347 (CH5183284)
Description: Debio1347 (CH5183284) tablets for oral administration
Study NCT00763620 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: catheter for mini bronchoalveolar lavage
Description: For each patient included an endotracheal aspiration and a mini bronchoalveolar lavage will be performed. After local anaesthesia, a suction catheter will be introduced in trachea by nasotracheal way. An endotracheal aspirate will be performed. Then, the mini bronchoalveolar lavage will be performed with the specific catheter introduced through the suction catheter. Expectorated sputum will also be ordered. This procedure will be performed once at the admission patient in intensive care unit.
Study NCT02109783 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine 2mg
Description: Caffeine 2 mg versus 4 mg/kg or placebo
Study NCT02109783 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine 4 mg
Description: To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects. Subjects will perform 4 exercise tests.
Study NCT02109783 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Caffeine 0
Description: To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects. Subjects will perform 4 exercise tests.
Study NCT03715881 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral prednisolone administration 50 mg
Description: 50 mg oral prednisolone from the onset of the disease for 1 week, with the dose gradually reduced within 2 weeks and then discontinued
Study NCT01245400 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Z-Lig
Description: ACL replacement
Study NCT01245400 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: allograft
Description: ACL replacement
Study NCT02966275 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glucagon-only bionic pancreas - glucagon
Description: A computer algorithm will automatically deliver glucagon based on the signal from a minimally invasive continuous glucose monitor.
Study NCT02966275 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Glucagon-only bionic pancreas - placebo
Description: A computer algorithm will automatically deliver placebo based on the signal from a minimally invasive continuous glucose monitor.
Study NCT04348435 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Saline
Study NCT01011088 — intervention group
Intervention type: OTHER
Description: Not any artificial interventions were given
Study NCT02928666 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DSS for mitigating interactions between recommendations
Description: DSS that detects and mitigates interactions between recommendations, proposing a set of non-conflicting guideline recommendations
Study NCT01804491 — intervention group
Intervention type: OTHER
Intervention: Motion Analysis
Description: 3D Motion analysis with retroflective markers on the skin (Vicon camera system) of the foot and lower leg (kinematics), walking over force plate (kinetics) and pressure plates (plantar pressure distribution).
Study NCT02393248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT02393248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Study NCT02393248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study NCT02393248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Study NCT02393248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Study NCT02393248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT04669691 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 antigen combined with MF59 adjuvant
Description: Eligible subjects will be stratified by age at the time of enrollment into one of 2 age cohorts and within each age cohort will be randomly assigned (equally) to 1 of 6 study vaccine groups. Subjects in each study vaccine group will be scheduled to receive 2 injections of aH5N1 vaccine 3 weeks apart
Study NCT03761589 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AFL Intervention
Description: The AFL intervention consisted of two 90-minute sessions per week for 12 months for both children and parents. The child physical activity sessions, held separately from the parent sessions, aimed to achieve 60 minutes of moderate-to-vigorous physical activity during each session through structured play activities, athletic drills, and sport exercises. Child dietary behaviors were taught through educational activities in small groups. For the parent program, behavior modification techniques were used to guide parents toward changing their own and their child's behavior. Take-home materials for self-monitoring of behaviors were used for both the child and the parent in order to reinforce concepts discussed in class.
Study NCT03761589 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wait-List Control
Description: Families that were randomly assigned to the wait-list control group were asked not to change their normal physical activity or dietary behaviors for the duration of the 12-week waiting period. They were asked to participate in the baseline and 12-week evaluations and then they were enrolled to receive the 12-week intervention.
Study NCT03730714 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local Anesthetic, Epinephrine and Morphine
Description: local anesthesia Bupivacaine 0.5% 20 ml (no more than 2 mg/kg) plus lidocaine 2% 10 ml (no more than 3 mg/kg) mixed together, plus epinephrine 5 mcg/ml (max 150 mcg), combined with morphine 0.1 mg/kg (max10 mg)
Study NCT03730714 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local Anesthetic, Epinephrine, Morphine and Surgicel
Description: Surgicel soaked with mixture of: local anesthesia Bupivacaine 0.5% 20 ml (no more than 2 mg/kg) plus lidocaine 2% 10 ml (no more than 3 mg/kg) mixed together, plus epinephrine 5 mcg/ml (max 150 mcg), combined with morphine 0.1 mg/kg (max10 mg)
Study NCT03730714 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: normal saline 0.9% to soak the surgicel according to the planned technique
Study NCT02572297 — intervention group
Intervention type: OTHER
Intervention: video-EEG
Description: Registration of seizures during video-EEG
Study NCT00992056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nebivolol
Description: 5 mg titrated to 10 mg daily versus matching placebo
Study NCT00992056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: Metoprolol 50 mg titrated to 100 mg
Study NCT00969163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: testosterone gel
Description: 300 ug or 2.5 mg transdermal testosterone gel daily for 6 weeks
Study NCT00969163 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: transdermal placebo gel for 6 weeks
Study NCT04294381 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision tool
Description: participants will be asked to use a decision tool to choose and delineate SMART health behavior goals
Study NCT00843258 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abduction treatment
Description: Abduction treatment with a Frejka's pillow for 6 weeks
Study NCT03983720 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of degree chronic fatigue.
Description: Evaluation of degree chronic fatigue with the results of survey Fatigue Severity Scale (FSS) and Modified Fatigue Impact Scale (MFIS). This result will allow to divide patients in groups : lowly fatigued and highly fatigued.
Study NCT02679781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral midazolam
Description: administration of 0.5mg/kg oral midazolam. During dental treatment 50% nitrous oxide/ 50% oxygen will be administered via nasal hood.